Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: INC Research | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: INC Research

Revenue up 13% in the quarter with backlog up 17%

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

INC Research
 
3Q Revenues: $234.5 million (+13%)

3Q Earnings: $37.8 million (earnings were $12.6 million 3Q14)

YTD Revenues: $673.4 million (+13%)

YTD Earnings: $86.4 million (earnings were $26.3 million 3Q14)

Comments: Revenue grew across all therapeutic areas, particularly in the central nervous system, oncology and other complex therapeutic areas. Backlog grew 17% to $1.8 billion in the quarter. Net new business awards were $327.7 million, representing a book-to-bill ratio of 1.4x, for the three months ended. Service revenue for the three and nine months ended September 30, 2014 have been adjusted by $4.5 million and $9.0 million, respectively, to remove the impact of the higher-than-normal change order activity. Restructuring and other costs consist of: severance costs associated with a reduction of, and lease obligation and termination costs in connection with abandonment and closure of redundant facilities.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters